Peter A. Kaufman

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacology +17

The Role of Relational Information Processes and Technology Use in Customer Relationship Management

Satish Jayachandran, Subhash Sharma, Peter A. Kaufman et al. · Journal of Marketing · 2005 · 970 citations

Business, Information Systems, Management Information Systems +8

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14